Compare Abbott Laboratories (ABT) vs Crowdstrike Holdings Inc (CRWD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Abbott Laboratories vs Crowdstrike Holdings Inc — how do they compare? Abbott Laboratories trades at $110.97 (market cap $187.95B), while Crowdstrike Holdings Inc trades at $221.69 (market cap $225.95B). The key difference: Crowdstrike Holdings Inc is the larger of the two by market cap, and Abbott Laboratories pays a 2.32% dividend while Crowdstrike Holdings Inc pays none. Which is the better fit depends on your goals.
| ABT | CRWD | |
|---|---|---|
Market Cap | $187.95B | $225.95B |
Sector | Health | Technology |
52-Week High | $136.62 | $225.16 |
52-Week Low | $82.57 | $87.56 |
Enterprise Value | $214.96B | $222.22B |
Dividend Yield | 2.32% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Abbott Laboratories (ABT) trades at $108.63, up 0.77% today, near its 52-week high. The stock shows a bullish technical trend with strong moving averages, though RSI indicates overbought conditions. Fundamentally, revenue grew to $44.33B in 2025 with a net income margin of 11.65%, while recent Q1 and Q2 2026 earnings beat expectations. The company maintains solid cash flow from operations of $9.57B and recently secured CE Mark for innovative dual glucose-ketone sensors, reinforcing its healthcare leadership.
Outlook remains positive with a consensus price target of $120.70, implying 11% upside, supported by 75.6% analyst buy ratings. Key risks include competitive pressures in diagnostics and macroeconomic sensitivity. The dividend yield and innovation pipeline offer stability, but investors should monitor execution on growth initiatives amid evolving market conditions.
CrowdStrike (CRWD) trades at $221.85, down 1.47% on the day, with a bullish technical outlook from moving averages but overbought RSI signals. Revenue growth remains strong, reaching $3.95 billion in 2025, though net income margins are negative. Recent news highlights leadership in cybersecurity and AI-driven threat detection, with the stock up 106% over six months. A 1:4 stock split occurred on July 2, 2026.
The stock offers growth exposure to cybersecurity demand, supported by analyst optimism and platform consolidation, but carries high valuation multiples and profitability risks. Upside depends on sustained revenue expansion and margin improvement, while volatility and competitive pressures pose challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abbott Laboratories
Abbott manufactures and markets medical devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, molecular diagnostic platforms, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
Read more on ABT →About Crowdstrike Holdings Inc
CrowdStrike Holdings provides cybersecurity products and services aimed at protecting organizations from cyberthreats. It offers cloud-delivered protection across endpoints, cloud workloads, identity and data, and threat intelligence, managed security services, IT operations management, threat hunting, identity protection, and log management. CrowdStrike went public in 2019 and serves customers worldwide.
Read more on CRWD →
